Literature DB >> 32050050

A hierarchical testing approach for detecting safety signals in clinical trials.

Xianming Tan1, Bingshu E Chen2, Jianping Sun3, Tejendra Patel4, Joseph G Ibrahim1.   

Abstract

Detecting safety signals in clinical trial safety data is known to be challenging due to high dimensionality, rare occurrence, weak signal, and complex dependence. We propose a new hierarchical testing approach for analyzing safety data from a typical randomized clinical trial. This approach accounts for the hierarchical structure of adverse events (AEs), that is, AEs are categorized by system organ class (SOC). Our approach contains two steps: the first step tests, for each SOC, whether any AEs within this SOC are differently distributed between treatment arms; and the second step identifies signal AEs from SOCs passing the first step tests. We show the superiority, in terms of power of detecting safety signals given controlled false discovery rate, of the new approach comparing with currently available approaches through simulation studies. We also demonstrate this approach with two real data examples.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MiST; clinical trials; drug safety; hierarchical testing; multiplicity; signal detection

Mesh:

Year:  2020        PMID: 32050050      PMCID: PMC8258607          DOI: 10.1002/sim.8495

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  False Discovery Rate Control With Groups.

Authors:  James X Hu; Hongyu Zhao; Harrison H Zhou
Journal:  J Am Stat Assoc       Date:  2010-09-01       Impact factor: 5.033

2.  Use of the false discovery rate for evaluating clinical safety data.

Authors:  Devan V Mehrotra; Joseph F Heyse
Journal:  Stat Methods Med Res       Date:  2004-06       Impact factor: 3.021

Review 3.  What have we learnt from Vioxx?

Authors:  Harlan M Krumholz; Joseph S Ross; Amos H Presler; David S Egilman
Journal:  BMJ       Date:  2007-01-20

4.  Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data.

Authors:  Bingshan Li; Suzanne M Leal
Journal:  Am J Hum Genet       Date:  2008-08-07       Impact factor: 11.025

5.  Planning and core analyses for periodic aggregate safety data reviews.

Authors:  H Amy Xia; Brenda J Crowe; Robert C Schriver; Manfred Oster; David B Hall
Journal:  Clin Trials       Date:  2011-01-26       Impact factor: 2.486

6.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

7.  Statistical Evaluation of Drug Safety Data.

Authors:  H Amy Xia; Qi Jiang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

8.  Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

Authors:  W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal
Journal:  Addiction       Date:  1998-04       Impact factor: 6.526

Review 10.  Statistical tests for differential expression in cDNA microarray experiments.

Authors:  Xiangqin Cui; Gary A Churchill
Journal:  Genome Biol       Date:  2003-03-17       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.